Michael G. Schlieman

Author

Also Known As

Michael G Schlieman, Michael G. Schlieman, Michael Schlieman

Publications

601

Citations

H-Index

Concepts

All Affiliations

Michael G. Schlieman is an author at University of California Davis Medical Center specializing in medicine, oncology, and cancer research.

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	239
2	Pharmacology	2	2	184
3	Cell Biology	1	1	55
4	Immunology	1	1	125
5	Cancer Therapeutics	1	1	59

Michael G. Schlieman

Publications

564

Citations

H-Index

Page 1

	Year	Citations
Utility of Tumor Markers in Determining Resectability of Pancreatic Cancer Michael G. Schlieman Archives of Surgery	2003	172
Targeting BCL-2 overexpression in various human malignancies through NF-κB inhibition by the proteasome inhibitor bortezomib Bridget N. Fahy, Michael G. Schlieman, Melinda M. Mortenson, Cancer Chemotherapy and Pharmacology Hematological MalignancyTumor BiologyBcl-2 OverexpressionOncologyMedicine	2005	125
Inhibition of AKT abrogates chemotherapy- induced NF-κB survival mechanisms: implications for therapy in pancreatic cancer1 Bridget N. Fahy, Michael G. Schlieman, Subbulakshmi Virudachalam, Journal of the American College of Surgeons	2004	99
Schedule-dependent molecular effects of the proteasome inhibitor bortezomib and gemcitabine in pancreatic cancer Bridget N. Fahy, Michael G. Schlieman, S. Virudachalam, Journal of Surgical Research Pancreatic CancerMedicinePharmacologyProteasome Inhibitor BortezomibSchedule-dependent Molecular Effects	2003	59
Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer Melinda M. Mortenson, Michael G. Schlieman, Subbulakshmi Virudachalam, Lung Cancer Proteasome InhibitionMedicineApoptosisCell DeathCancer Biology	2005	55
BCL‐2 functions as an activator of the AKT signaling pathway in pancreatic cancer Melinda M. Mortenson, Joseph G. Galante, Oren Gilad, Journal of Cellular Biochemistry	2007	54

Page 1